INNV · NASDAQ · Medical - Care Facilities

InnovAge (INNV)

Runs PACE centers that coordinate medical and support care for frail seniors.

$9.62
vs last close−1.04 (−9.76%)
Loading prices…

InnovAge Holding Corp.INNV
Health Care

Operates PACE centers that coordinate medical, therapy, behavioral health, pharmacy, meals, transportation, and care management for frail seniors. Revenue comes mainly from government capitation payments, and the model is concentrated in U.S. community-based care under Medicare, Medicaid, VA, and state oversight.

Runs one reportable segment, PACE, built around community centers for frail, mostly dual-eligible seniors. Named services include in-center primary care, physical, occupational and speech therapy, dental care, mental health and psychiatric services, meals, activities, transportation, pharmacy, and care management.

Operations are concentrated in the United States across several states. The model coordinates an interdisciplinary care plan intended to keep nursing-home-eligible participants in their homes and communities where possible, with enrollment growth tied to center capacity and utilization.

Revenue comes from capitation payments from Medicare, Medicaid, the Veterans Administration, and private-pay sources. Because InnovAge is at risk for participant care costs and operates under CMS and state oversight, execution depends on care quality, staffing, enrollment permissions, and regulatory remediation obligations.

Company facts

CEOPatrick Blair
ListedMar 4, 2021
ExchangeNASDAQ
HeadquartersDenver, CO
CountryUnited States
Employees2,440
CIK0001834376
ISINUS45784A1043

Market cap$1.45B
EPS (ttm)−$0.0221
P/E (ttm)−482.35
ROE-1.1%
P/B6.14
P/S1.46
Dividend yieldDiv yield
Beta0.75vs XLV 1.18

Price target$14.00+31.3%Average of 9 analysts
ConsensusHold6 of 9 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 9, 2026KeyBancReiterate
Rating: Target: $13
Rating: OverweightTarget: $14
Aug 21, 2026KeyBancUpgrade
Rating: Sector WeightTarget:
Rating: OverweightTarget: $13
Dec 17, 2024JP MorganDowngrade
Rating: Neutral
Rating: Underweight

Next report
Nov 3, 26
in 41 days
EPS estimate
$0.11
Revenue estimate
$257.2M
Fiscal quarter
Q1 FY27

EPSReportedEstimate

Feb '25May '25Sep '25Nov '25Feb '26May '26Sep '26Nov '26
Reported−$0.10−$0.08−$0.01$0.06$0.08−$0.22$0.06Pending
Estimate−$0.01−$0.02−$0.02$0.01$0.04$0.06$0.07$0.11
Surprise−766.6%−300.0%+50.0%+500.0%+100.0%−466.7%−19.6%

RevenueReportedEstimate

Feb '25May '25Sep '25Nov '25Feb '26May '26Sep '26Nov '26
Reported$209.0M$218.1M$221.4M$236.1M$239.7M$251.9M$262.0MPending
Estimate$210.2M$214.1M$219.7M$226.5M$228.4M$234.3M$238.3M$257.2M
Surprise−0.6%+1.9%+0.8%+4.2%+5.0%+7.5%+9.9%
Estimate$0.11
ReportedDue Nov 3, 2026
Estimate$257.2M
ReportedDue Nov 3, 2026
View details

Debt to equity36.90%
Current ratio105.10%

ProfitabilityRevenueNet incomeNet margin

Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue$205.1M$209.0M$218.1M$218.1M$236.1M$239.7M$251.9M$262.0M
Net income−$4.9M−$13.2M−$11.4M−$11.4M$8.0M$10.6M−$29.5M$8.3M
Net margin0.0%0.0%0.0%0.0%3.4%4.4%0.0%3.2%

GrowthOperating income

Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Operating income−$4.9M−$12.6M−$10.2M−$10.2M$8.3M$16.1M$22.8M$16.0M
YoY growthLoss narrowedLoss widenedLoss widenedLoss widenedTurned profitTurned profitTurned profitTurned profit

Balance sheet, Jun 30, 2026Cash & short-term investments $141.3M · Total debt $87.0M · Total assets $557.4M · Shareholders' equity $235.6M

Revenue
$262.0M
Operating income
$16.0M
Net income
$8.3M
View details

No dividends on record.

Institutions≈ 13.64%18.61M shares
110 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail
Insiders1.38%1.89M shares
14 holders · as of Aug 17, 2026
Other≈ 84.98%115.95M shares
remainder

136.45M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
T. Rowe Price Investment Management, Inc.Institution
4.49%6.12Mas of Jun 30, 2026
Federated Hermes, Inc.Institution
1.40%1.90Mas of Jun 30, 2026
BlackRock, Inc.Institution
1.09%1.49Mas of Jun 30, 2026
Vanguard Capital Management LLCInstitution
0.69%935,264as of Jun 30, 2026
Patrick T. BlairInsiderofficer: CHIEF EXECUTIVE OFFICER
0.55%751,047filed Jul 27, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Nov 14, 2025Michael Anthony Scarbroughofficer: President and COO−33,000$4.90
View details

  • UnitedHealth Group

    Broad Medicare, Medicaid, and Optum care-delivery alternative

  • Humana

    Medicare Advantage, D-SNP, CenterWell, and home-care overlap

  • CVS Health

    Aetna benefits plus Oak Street and Signify care-delivery overlap

  • Molina Healthcare

    Medicaid and dual-eligible managed care for high-acuity members

  • Centene

    Medicaid, high-acuity, and D-SNP managed-care substitute

  • Alignment Healthcare

    Senior-focused Medicare Advantage care model in overlapping markets

  • Addus HomeCare

    In-home personal care, home health, and hospice for dual eligibles

  • The Ensign Group

    Skilled nursing and senior living alternative for frail seniors

Compare

CompanyPriceChange
InnovAge$9.62−9.76%$1.45B20.61.5+18.3%
UnitedHealth Group$368.33−1.24%$338.69B24.017.30.8+0.4%
Humana$371.06−0.23%$44.66B35.230.10.3+26.2%
CVS Health$86.02−1.24%$111.13B23.010.60.3+7.3%
Molina Healthcare$188.83−1.23%$9.98B1,006.326.80.2−4.8%
Centene$62.62−1.07%$31.26B13.90.2+9.9%
Alignment Healthcare$7.73−3.32%$1.66B42.827.90.4+31.6%
Addus HomeCare$114.91+0.59%$2.13B20.016.01.4+8.0%
The Ensign Group$177.71+0.79%$10.28B27.621.71.9+17.3%
Median27.619.50.3+9.0%